Open Access This article is
- freely available
Toxins 2019, 11(2), 115; https://doi.org/10.3390/toxins11020115
Correction: Field, M. et al. AbobotulinumtoxinA (Dysport®), OnabotulinumtoxinA (Botox®), and IncobotulinumtoxinA (Xeomin®) Neurotoxin Content and Potential Implications for Duration of Response in Patients
Ipsen Bioinnovation, Abingdon OX14 4RY, UK
Ipsen Pharma, Cambridge, MA 02142, USA
TNO—CBRN Protection, 2288GJ Rijswijk, The Netherlands
Ipsen Biopharmaceuticals, Basking Ridge, NJ 07920, USA
Author to whom correspondence should be addressed.
Received: 12 February 2019 / Accepted: 13 February 2019 / Published: 13 February 2019
The authors wish to make the following corrections to their paper .
Daniel Snyder should be listed as the author of their paper and the fourth affiliation “Ipsen Biopharmaceuticals, Basking Ridge, NJ 07920, USA; [email protected]” should be added.
In the first affiliation, the original email address of Malgorzata Field is [email protected]. This correct email address should be replaced by [email protected]
The “Author Contribution” section should be replaced by “Conceptualisation, M.F., A.S., P.P., D.S. and K.F.; Formal analysis, M.F., M.v.d.S., J.L. and D.N.; Investigation, M.F. and M.v.d.S.; Methodology, M.F., A.S., P.P., K.F. and M.v.d.S.; Validation, M.F., M.v.d.S., J.L. and D.N.; Visualisation, M.F., M.v.d.S., J.L. and D.N.; Writing—review & editing, M.F., A.S., P.P., M.v.d.S., J.L., D.N. and K.F. M.v.d.S., J.L. and D.N. were only involved in the EndoPep analyses.”
The “Conflicts of Interest” section should be replaced by “A.S., K.F. and P.P. are employed by Ipsen Pharma. D.S. and M.F. are ex-employees of Ipsen Pharma. M.v.d.S., J.L. and D.N. are employed by TNO.”
The manuscript will be updated and the original will remain online on the article webpage. We apologize for any inconvenience caused to our readers.
- Field, M.; Splevins, A.; Picaut, P.; Van der Schans, M.; Langenberg, J.; Noort, D.; Foster, K. AbobotulinumtoxinA (Dysport®), OnabotulinumtoxinA (Botox®), and IncobotulinumtoxinA (Xeomin®) Neurotoxin Content and Potential Implications for Duration of Response in Patients. Toxins 2018, 10, 535. [Google Scholar] [CrossRef] [PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).